Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-17A


Brief Information

Name:Interleukin 17A
Target Synonym:Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8),CTLA8,IL17A,Interleukin 17A,Cytotoxic T-Lymphocyte-Associated Antigen 8,Cytotoxic T-Lymphocyte-Associated Protein 8,CTLA-8,IL-17A,IL-17,IL17,Interleukin-17A
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved


Project Name Modality Therapeutic Area Indications Stage Right Available
IL17A mAb Monospecific antibody Immunological disease Psoriasis,Axial spondyloarthritis SpA Phase III Global  (except China)

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CT8-M5240-Cell-based assay

Mouse IL-17A, His Tag (Cat. No. CT8-M5240) stimulates secretion of IL-6 by NIH-3T3 cells. The ED50 for this effect is 2.132-5.005 ng/mL.


Loaded Biotinylated Human IL17A, His,Avitag (Cat. No. ILA-H82Q1) on SA Biosensor, can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with an affinity constant of 18.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human IL-17 RA, Fc Tag (Cat. No. ILA-H5257) on Protein A Biosensor, can bind Mouse IL-17A, His Tag (Cat. No. CT8-M5240) with an affinity constant of 20.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Virulizin Approved Aptose Virulizin, Virulizin-2 gamma Mexico Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell null 1997-01-01 Stomach Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Uterine Cervical Neoplasms; Sarcoma, Kaposi; Melanoma Details
Secukinumab NVP-AIN-457; AIN-457; KB-03303A Approved Novartis Pharma Ag Cosentyx, 可善挺 Japan Psoriasis; Arthritis, Psoriatic Novartis Pharma Ag 2014-12-26 Uveitis; Polymyalgia Rheumatica; Graves Ophthalmopathy; Psoriasis; Hyperkeratosis, Epidermolytic; Tendinopathy; Arthritis, Psoriatic; Parapsoriasis; Lichen Planus; Tendon Injuries; Asthma; Multiple Sclerosis; Hidradenitis Suppurativa; Arthritis; Inflammation; Ichthyosiform Erythroderma, Congenital; Plaque psoriasis; Dermatitis, Atopic; Gastroenteritis; Behcet Syndrome; Crohn Disease; Spondylitis, Ankylosing; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Necrobiosis Lipoidica; Non-alcoholic Fatty Liver Disease; Giant Cell Arteritis; Inflammatory Bowel Diseases; Alopecia Areata; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Non-radiographic axial spondyloarthritis; Spondylarthritis; Ichthyosis; Arthritis, Rheumatoid; Rotator Cuff Injuries; Spondylarthropathies; Netherton Syndrome; Lupus Nephritis; Ichthyosis, Lamellar; Arthritis, Juvenile Details
Ixekizumab LY-2439821 Approved Eli Lilly And Company 拓咨, Taltz United States Psoriasis Eli Lilly And Company 2016-03-22 Non-radiographic axial spondyloarthritis; Depressive Disorder, Major; Pyoderma Gangrenosum; Spondylitis, Ankylosing; Spondylarthritis; Arthritis, Rheumatoid; Psoriasis; Arthritis, Psoriatic; Lichen Planus; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
UCB-0159 UCB-0159 Phase 1 Clinical Ucb Sa Autoimmune Diseases Details
Isomyosamine MYMD-1 Phase 2 Clinical Mymd Pharmaceuticals Inc Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation Details
QX002N QX-002N Phase 2 Clinical Spondylitis, Ankylosing Details
ZL-1102 ZL-1102; CB-001 Phase 1 Clinical Crescendo Biologics Ltd, Zai Lab (Shanghai) Co Ltd Psoriasis Details
CJM-112 CJM-112 Phase 1 Clinical Novartis Pharma Ag Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Sclerosis; Multiple Myeloma; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
JNJ-61178104 JNJ-61178104 Phase 1 Clinical Janssen Global Services Llc Autoimmune Diseases Details
Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) JS005 Phase 2 Clinical Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis Details
JNJ-63823539 JNJ-63823539 Phase 1 Clinical Janssen Global Services Llc Arthritis, Rheumatoid Details
Izokibep AFB-035; ABY-035; IMG-020; IMG020 Phase 3 Clinical Affibody Ab Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis Details
LEO-153339 LEO-153339 Phase 1 Clinical Leo Pharma Inc Details
IMU-935 IMU-935 Phase 1 Clinical Immunic Ag Prostatic Neoplasms Details
DMT-310 DMT-310 Phase 2 Clinical Dermata Rosacea Details
HY-1770 HY1770; HT-17; HT17; HY-1770 Phase 1 Clinical Plaque psoriasis; Dermatitis, Atopic Details
CMAB-015 CMAB015; CMAB-015 Phase 1 Clinical Taizhou Mabtech Pharmaceutical Co Ltd Spondylitis, Ankylosing; Plaque psoriasis Details
Secukinumab biosimilar (Bio-Thera Solutions) BAT-2306 Phase 3 Clinical Bio-Thera Solutions Ltd Autoimmune Diseases; Psoriasis; Plaque psoriasis Details
SSGJ-608 608; SSGJ-608 Phase 3 Clinical Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd Psoriasis; Plaque psoriasis Details
Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) LZM-012; LZM012; XKH004; XKH-004 Phase 2 Clinical Beijing Kanova Biomedical Technology Co Ltd, Livzon Pharmaceutical Group Inc Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis Details
Xeligekimab GR-1501 Phase 3 Clinical Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd, Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd Spondylarthritis; Lupus Nephritis; Psoriasis; Plaque psoriasis Details
Vunakizumab SHR-1314 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Spondylarthritis; Spondylitis, Ankylosing; Autoimmune Diseases; Graves Ophthalmopathy; Lupus Nephritis; Psoriasis; Graves Disease; Arthritis, Psoriatic; Plaque psoriasis Details
Gumokimab AK-111 Phase 3 Clinical Spondylitis, Ankylosing; Spondylarthritis; Psoriasis; Plaque psoriasis Details
Sonelokimab M-1095; ALX-0761; MSB-0010841 Phase 2 Clinical Ablynx Nv Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message